{"id":"r-da-epoch-21","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-60%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This regimen is designed to target and kill rapidly dividing cancer cells. The combination of drugs works synergistically to induce apoptosis and inhibit cell proliferation.","oneSentence":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:06.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT03213977","phase":"PHASE3","title":"R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Medical University","startDate":"2017-07-10","conditions":"Diffuse Large B-cell Lymphoma","enrollment":475},{"nctId":"NCT03479918","phase":"PHASE3","title":"R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)","status":"UNKNOWN","sponsor":"Elena N.Parovichnikova","startDate":"2018-03-15","conditions":"Lymphoma, High-Grade","enrollment":80},{"nctId":"NCT02842931","phase":"PHASE3","title":"R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2015-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["R-DA-EPOCH"],"phase":"phase_3","status":"active","brandName":"R-DA-EPOCH-21","genericName":"R-DA-EPOCH-21","companyName":"National Research Center for Hematology, Russia","companyId":"national-research-center-for-hematology-russia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone. Used for Diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}